No "black box" for epilepsy meds?

It was a close shave for 11 epilepsy drugs yesterday. An FDA advisory panel agreed that they may raise the risk of suicide--but not enough to warrant a "black box" warning on their labels. You'll recall that the agency did a meta-analysis of trial data and found higher rates of suicidal behavior and thinking in dozens of studies. FDA staffers have been indicating for weeks that they intended to issue a warning based on that analysis. And that warning would affect products made by almost every big name in pharma: GlaxoSmithKline, Pfizer, Merck, et al.

It wasn't a close vote at the meeting, however; 14 panelists voted against a "black box", with four in favor and three abstaining. The expert panelists did recommend sending a medication guide to doctors that details the risk of suicide possible with these meds. And in a separate vote the panelists affirmed the agency's conclusions about the suicide risks. Despite voting against the "black box," one panelist said, "I do think there's a serious need to communicate this knowledge." The panelists just wanted to make sure that the warning wasn't so strong that it scared patients off drug therapy.

The 11 meds--which bring in a combined $10 billion-plus annually--aren't totally out of the woods yet. The FDA generally follows its panels' advice, but doesn't have to. You can bet the drugmakers who sell those products will be watching closely.

- read the article in the International Herald Tribune
- check out the Wall Street Journal story

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.